Background: Acute pancreatitis is an inflammatory disease of the pancreas classified as severe, is associated with high morbidity and mortality. Various methods are available to predict the severity and outcome of acute pancreatitis. Aims and Objective: The present study was aimed to find out the utility of serum procalcitonin in predicting the severity and outcome of acute pancreatitis. Material and Methods: This study was carried in department of surgery and department of medicine, Muzaffarnagar Medical College, Muzaffarnagar from June 2022 to February 2023. This study includes 67 acute pancreatitis patients and all the investigation were done on fully auto-analyzer (Access-2). Results: In this study, the serum procalcitonin (PCT) was found below 0.5 n g /ml in 62.69% (42 out of 67) patients, out of these, none had any complication, antibiotics use, low CT Severity Index (CTSI) score, early recovery and no death. Serum procalcitonin (PCT) was increased significantly in 37.31% (25 out of 67) patients. CTSI score in 20 of these patients were greater than 5. Hypotension and respiratory failure were seen in 21 and 20 patients respectively with a significant p value of 0.001. Antibiotic use was observed in all the 25 patients in this group. Duration of hospital stay was longer in patients with increased procalcitonin level. Five participants with mean procalcitonin level 4.29 ng/ml were died due to the complications related to acute severe pancreatitis. Conclusion: Serum procalcitonin can be a new promising marker to predict severity and outcome of acute pancreatitis.